{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T22:07:27Z","timestamp":1780610847854,"version":"3.54.1"},"reference-count":16,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,25]],"date-time":"2024-11-25T00:00:00Z","timestamp":1732492800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010355","name":"Hellenic Society of Medical Oncology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010355","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","award":["HE_6B\/16"],"award-info":[{"award-number":["HE_6B\/16"]}],"id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmogastro.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Gastrointestinal Oncology"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.esmogo.2024.100120","type":"journal-article","created":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T04:44:17Z","timestamp":1736311457000},"page":"100120","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Anti-EGFR re-challenge with chemotherapy in RAS wild-type advanced colorectal cancer (A-REPEAT study): efficacy and correlations with tissue and plasma genotyping"],"prefix":"10.1016","volume":"7","author":[{"given":"J.","family":"Sgouros","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8459-7163","authenticated-orcid":false,"given":"A.","family":"Eliades","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Papadopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Korfiatis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Papamichael","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Fountzilas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Tsolaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Achilleos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7454-0454","authenticated-orcid":false,"given":"K.","family":"Tsangaras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Loizides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Oikonomopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T.","family":"Makatsoris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Kypri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Ioannides","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5670-8329","authenticated-orcid":false,"given":"G.","family":"Koumbaris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Fountzilas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0662-460X","authenticated-orcid":false,"given":"P.C.","family":"Patsalis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6632-2462","authenticated-orcid":false,"given":"G.","family":"Pentheroudakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.esmogo.2024.100120_bib1","doi-asserted-by":"crossref","DOI":"10.1002\/ijc.33588","article-title":"Cancer statistics for the year 2020: an overview","author":"Ferlay","year":"2021","journal-title":"Int J Cancer"},{"issue":"4","key":"10.1016\/j.esmogo.2024.100120_bib2","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1002\/bjs5.50299","article-title":"Incidence and management of patients with colorectal cancer and synchronous and metachronous colorectal metastases: a population-based study","volume":"4","author":"Vayrynen","year":"2020","journal-title":"BJS Open"},{"key":"10.1016\/j.esmogo.2024.100120_bib3","series-title":"NCCN Clinical Practice Guidelines in Oncology (NCCN guidelines), Colon Cancer, Version 4","year":"2024"},{"issue":"1","key":"10.1016\/j.esmogo.2024.100120_bib4","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.annonc.2022.10.003","article-title":"Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Cervantes","year":"2023","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.esmogo.2024.100120_bib5","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1136\/jclinpath-2018-205471","article-title":"RAS genes in colorectal carcinoma: pathogenesis, testing guidelines and treatment implications","volume":"72","author":"Saeed","year":"2019","journal-title":"J\u00a0Clin Pathol"},{"issue":"8","key":"10.1016\/j.esmogo.2024.100120_bib6","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1038\/s41591-022-01886-0","article-title":"Circulating tumor\u00a0DNA to guide rechallenge with panitumumab in metastatic colorectal cancer: the phase 2 CHRONOS trial","volume":"28","author":"Sartore-Bianchi","year":"2022","journal-title":"Nat Med"},{"issue":"9","key":"10.1016\/j.esmogo.2024.100120_bib7","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1093\/annonc\/mdr623","article-title":"Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance?","volume":"23","author":"Santini","year":"2012","journal-title":"Ann Oncol"},{"issue":"86","key":"10.1016\/j.esmogo.2024.100120_bib8","doi-asserted-by":"crossref","first-page":"35623","DOI":"10.18632\/oncotarget.26256","article-title":"Prognostic significance of tumor genotypes and CD8+ infiltrates in stage I-III colorectal cancer","volume":"9","author":"Fountzilas","year":"2018","journal-title":"Oncotarget"},{"issue":"8","key":"10.1016\/j.esmogo.2024.100120_bib10","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1093\/annonc\/mdx175","article-title":"Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials","volume":"28","author":"Arnold","year":"2017","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.esmogo.2024.100120_bib11","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1001\/jamaoncol.2018.5080","article-title":"Rechallenge for patients with RAS and BRAF wild-type metastatic colorectal cancer with acquired resistance to first-line cetuximab and irinotecan: a phase 2 single-arm clinical trial","volume":"5","author":"Cremolini","year":"2019","journal-title":"JAMA Oncol"},{"issue":"7","key":"10.1016\/j.esmogo.2024.100120_bib12","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1001\/jamaoncol.2023.0655","article-title":"Panitumumab plus trifluridine-tipiracil as anti-epidermal growth factor receptor rechallenge therapy for refractory RAS wild-type metastatic colorectal cancer: a phase 2 randomized clinical trial","volume":"9","author":"Napolitano","year":"2023","journal-title":"JAMA Oncol"},{"issue":"10","key":"10.1016\/j.esmogo.2024.100120_bib13","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1001\/jamaoncol.2021.2915","article-title":"Cetuximab rechallenge plus avelumab in pretreated patients with RAS wild-type metastatic colorectal cancer: the phase 2 single-arm clinical CAVE trial","volume":"7","author":"Martinelli","year":"2021","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.esmogo.2024.100120_bib14","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1093\/annonc\/mdy509","article-title":"Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge","volume":"30","author":"Parseghian","year":"2019","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.esmogo.2024.100120_bib15","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.5635","article-title":"Anti-EGFR rechallenge in patients with refractory ctDNA RAS\/BRAF wt metastatic colorectal cancer: a nonrandomized controlled trial","volume":"7","author":"Ciardiello","year":"2024","journal-title":"JAMA Netw Open"},{"issue":"4","key":"10.1016\/j.esmogo.2024.100120_bib16","first-page":"314","article-title":"Rationale and study design of the PARERE trial: randomized phase II study of panitumumab re-treatment followed by regorafenib versus the reverse sequence in RAS and BRAF wild-type chemo-refractory metastatic colorectal cancer patients","volume":"20","author":"Moretto","year":"2021","journal-title":"Clin Colorectal Cancer"},{"issue":"1","key":"10.1016\/j.esmogo.2024.100120_bib17","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1186\/s12885-021-08395-2","article-title":"REMARRY and PURSUIT trials: liquid biopsy-guided rechallenge with anti-epidermal growth factor receptor (EGFR) therapy with panitumumab plus irinotecan for patients with plasma RAS wild-type metastatic colorectal cancer","volume":"21","author":"Nakajima","year":"2021","journal-title":"BMC Cancer"}],"container-title":["ESMO Gastrointestinal Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949819824000815?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2949819824000815?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T01:25:24Z","timestamp":1762651524000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2949819824000815"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":16,"alternative-id":["S2949819824000815"],"URL":"https:\/\/doi.org\/10.1016\/j.esmogo.2024.100120","relation":{},"ISSN":["2949-8198"],"issn-type":[{"value":"2949-8198","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Anti-EGFR re-challenge with chemotherapy in RAS wild-type advanced colorectal cancer (A-REPEAT study): efficacy and correlations with tissue and plasma genotyping","name":"articletitle","label":"Article Title"},{"value":"ESMO Gastrointestinal Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmogo.2024.100120","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100120"}}